This study examined dose-responserelationshipsbetween activatedrecombinantfactorVII(rFVIIa) and (1) in vivo haemostasis and (2) in vitro measures of coagulation and plateletfunction.Anesthetized swine were used.E ar bleeding time( BT)w as measured and blood was sampledfollowing increasing dosesof rFVIIa (0, 90, 180, 360 and 720 μg/kg; n=6) or saline (n =6). BT was not alteredbyrFVIIa. Prothrombin time(PT)using standard or pig-specific methods was decreasedbyrFVIIa.Activated clotting time (ACT)was decreasedbyrFVIIa.Thromboelastography using collagen (COLL) or pig thromboplastin (p-ThP) as agonist demonstrated shorterreaction times, shortenedtime to reach maximumv elocityo fc lot formation,and increased α -angle in the presence of rFVIIa. rFVIIa dosing increasedmaximumveloc-
Introduction
Activatedrecombinantfactor VII (rFVIIa) has been widelyused to treat bleeding complications in haemophilia patients. Recent reports suggest broaderapplications (1) .Currently, there is great interest in the potentialf or use of rFVIIai nt he treatment of haemorrhage after trauma (2, 3) . However, use for trauma is by no means provena nd advances in this area will continue to require experimental study.
The fewexperimental studies published that examine the use of rFVIIa in traumahavee xclusively used swine.Inone study, severe liverinjuries were induced in swine made coagulopathic by haemodilution and hypothermia; animals received either180 μ g/kg rFVIIaorsaline in addition to gauze packing. Blood loss wasreduced when rFVIIa wasused (4) . Asimilarstudy demonstrated thateither180 μ gor720 μ g/kg rFVIIareduced blood loss in coagulopathic pigs (5) .I np igs with normalc oagulation, rFVIIadecreased blood loss following liverinjuryinone study (6) butnot in twoothers (7, 8 ).
There appears to be twomechanisms by whichrFVIIa acts at pharmacologically relevant doses. One mechanism has beendescribedt hat involves direct binding of rFVIIa to activatedp latelets (9) . This leads to the generation of small amounts of activatedfactor Xand subsequentlythrombin, resulting in platelet activation, granule release, and furtherr ecruitment of platelets (9) . Theothermechanism of action requires binding of rFVIIa to exposed tissue factor on an appropriate surface followedb y enzymatic activation of factor X(10). The tissue factor-FVIIa interaction is species-specific (11, 12) . Forexample, human factor VII (FVII) appears to have reduced activity when exposed to porcine thromboplastin (11, 12) . Furthermore,standard in vitro coagulation tests commonlyu se as at issue factor source rabbit brain thromboplastin, whichreactsdifferently withhuman versus pig plasma (11) .When rabbit-derived reagentsa re used to assaypig blood that contains human rFVIIa, yetathirdspecies is introducedinto the assaysystem. This mayproduce asituation in whichagiven dose of rFVIIa hasmore apparent activity in pig blood when measured by in vitro tests thanthe same dose has in vivo when exposed solelytopig tissue factor.This could complicate interpretation of results.
This study wasconductedtodetermine the effectsofincreasing doses of rFVIIaon in vivo haemostasis and in vitro measures of coagulation and platelet function usings pecies-specific assays in swine with normalcoagulation function.
Methods
Experimental procedures were conducted in twophases. The objective of the first phase (DoseEscalation Phase)w as to determine the effectsofincreasing doses of rFVIIaoncapillary bleeding time and in vitro haemostatic parametersusing species-specificp rocedures. Thes econdp hase (InjuryP hase)w as ap ilot studyofthe effects of rFVIIapretreatment on the response to severe liverlaceration.
Animals
Crossbred commercial swine (DurocxMusclor xLarge White x Yo rkshire) weighing37.2 ± 0.8 kg (mean ± SEM) were used in this study. Animalsw ere maintainedinafacility accreditedb y the Association for the Assessment and Accreditation of LaboratoryAnimal Care,International. This study wasapprovedbythe Institutional Animal Care and Use Committee of the US Army Institute of Surgical Research,F ortS am Houston, Texas. Animals received humane care in accordance with the Guide for the Care and Useo fL aboratoryA nimals (National Institutes of Health publication 86-23, revised 1996) .
Animals were assignedrandomly to treatment groups. Treatment consisted of either1)increasing doses of rFVIIa(rFVIIa group; n=6), or 2) repeated infusions of physiological saline (saline group; n=6). Investigatorswere blindedtotreatment.Swine were fasted for24to36hours before the procedure, with water continuouslyavailable. Animals were sedated using glycopyrrolate,tiletamine HCl, and zolazepam.Theyw ere thenintubated and anesthetized( isoflurane in oxygen) using ac losedc ircuit systemwith mechanical ventilation. Digital temperatureprobes were placed on each ear,and heatlamps were positionedtomaintain ear temperature between 40 and 41°C. An infusion catheter wasp laced occlusivelyi naf emoral vein and advanced to the caudal vena cava.An8.5 Fr catheter introducer wasshortenedto 3cmand placed occlusively in afemoral artery for blood sampling. The oppositefemoral artery wascatheterized occlusively using aP aratrend7+M ultiparameter Sensor-catheter (DiametricsMedical Inc., Roseville,Minnesota)attached to aTrendcare TCM7 000 blood gasm onitoring system (Diametrics Medical Inc., Roseville, Minnesota) for continuous monitoring of body temperaturea nd blood pH. Ap orti nt he Paratrend7+c atheter wasc oupled to ac ontinuous data collection system (MicroMed ® ,Louisville, KY) for monitoring blood pressure and heart rate. Laparotomy, splenectomy, and cystotomyw ere performed on each pig. To compensate forremoval of the spleen, each animalw as infusedw ith lactated Ringer'ss olution at av olume equivalent to three timesthe spleenweight. Animals were stabilized for20minutesatabody temperatureof38.5 to 39.5°C, a blood pH of 7.37 to 7.43, and amean arterial pressure (MAP) between 50 and 80 mm Hg.
Dose escalation phase Tr eatmentadministration
Treatments were administered at 0, 20,40, 60, and 80 minutes. Treatments were infusedv ia the femoral vein catheter over a four-minute period using aPHD 2000infusion pump (Harvard Apparatus, Natick, MA). Afour-minute circulation period was allowedprior to furtherprocedures. Doses of rFVIIa were calculatedtoprovide the followingcumulative effectivedoses: 0 μ g/ kg at time0,90 μ g/kg at 20 minutes, 180 μ g/kg at 40 minutes, 360 μ g/kg at 60 minutes, and 720 μ g/kg at 80 minutes. Dose calculations accountedfor an estimated half-life for rFVIIaof147 minutes in the circulation (13) ,with the assumption thathalf-life wassimilarbetween humans and swine.The actual doses administered at each respective time pointwere: 0 μ g/kg, 90 μ g/kg, 96 μ g/kg, 192 μ g/kg, and 384 μ g/kg at 0, 20, 40, 60, and 80 minutes.
Earbleeding times
Ear bleeding time (BT) wasdeterminedatbaseline and after each treatment administration and circulation period.B Tw as performeds imultaneously in both ears by completelyp enetrating each using a#11 scalpel blade. Themean of the twoears wasrecorded as BT.Filterpaper wasusedtowickawayblood during the procedure.
In apilot experiment, the sensitivity of the BT procedurewas assessedinthreeadditional anesthetizedpigs in whichactivated clotting time (ACT) wase xtendedb yi nfusing heparin and reversed by infusingprotamine sulfate. At baseline,BTand ACT were 158 ± 88 (mean ±SEM) and 99 ± 95 seconds, respectively. Followingheparin, BT and ACTwere 317 ± 88 and 636 ± 95 seconds, respectively.Protamine decreased BT to 156 ± 88 seconds and ACTto145 ± 95 seconds.
Injuryphase
The peritoneal cavitywas suctionedimmediately before induction of the liveri njury( at 100m inutes).U sing as peciallyd esignedinstrument (14) ,apenetrating laceration wasmade in the rightcentral portion of the liversuch that the right medial lobar vein waslacerated approximately 3cmdistaltothe vena cava. The abdomen wastemporarily closed and the animalwas monitored withoutresuscitation. At 60 minutespost-injury, surviving animals were euthanized. Followingeuthanasia or earlier death, intraperitonealblood wasquantitated.
Bloodsampling
Bloodsamples were collected by inserting a20cmsingle-usecatheterm ade fromT ygon tubing( I.D.0 .9 mm; Saint Govaine Performance, AkronO H) into thes elf-sealing porto ft he catheterintroducer and gentlywithdrawing the blood to minimize shear-induced platelet activation. Thefirst 3mlofblood wasdiscarded. In the Dose Escalation Phase,b lood samplesw ere collected at baseline and after each respectivet reatment infusion and circulation period.Inthe InjuryPhase,ablood sample was collected at 30 minutesp ost-injury. Except for thromboelastography(TEG) samples, blood wasanticoagulated with 3.2% sodium citrate at 1partcitratesolution to 9parts blood.
At each time, hematocrit, plateletcount, fibrinogen concentration, factor VII activity,standard prothrombin time (PT), activatedp artialt hromboplastin time( aPTT), pig-specificP T (pPT), thrombin-antithrombin-III complex (TAT )concentration, and activatedclotting time (ACT) were determined. At baseline, after the 180 ug/kgand 720 ug/kg doses, and at 30 minutes postinjury, thromboelastography( TEG) and platelet aggregometry were alsoperformed.
Standardlaboratoryprocedures
Hematocrit (Hct) and platelet (PLT)c ounts were performed as direct measurementsusing the ABX Pentra 120 hematology analyzer (ABXDiagnostics, Inc.,Irvine,CA). ACTwas performed using the Hemochron Response (InternationalT echnidyne Corp.,E dison, NJ), according to manufacturer'si nstructions. FVII activity wasm easured with ao ne-stage clotting assay (FVII:C) using an ACLFutura Coagulation System (Instrumentation Laboratory, Lexington, MA). Fort he assay, normal and FVII deficient human plasma standards and rabbit brain thromboplastin reagent provided by the manufacturer were used. The ACLFutura methodology reports resultsinpercentactivity.Percentages were divided by 100 to convert to U/ml. Sampleswere diluteda sn ecessary according to manufacturer specifications. Mean FVII activity was1.06 ± 0.07 U/ml for pooled normal pig plasma, with intra-assayand interassaycoefficientsofvariation (CV) of 2.7% and 4.9%, respectively.S tandard prothrombin time (PT; using commercialrabbit brainreagent),activatedpartialthromboplastin time(aPTT), and fibrinogen concentrations were determinedat37°C using the ACLFutura Coagulation Systema ccording to manufacturer'si nstructions. Meanc lotting time for the standard PT assayusing poolednormal pig plasma was12.87 ± 0.15 sec,with intra-assayand interassayCVof1.2% and 4.7%, respectively.M ean aPTT using pooledn ormal pig plasma was14.40 ± 0.38 sec,with intra-assayand interassayCV of 1.2% and 2.6%, respectively.F ibrinogenc oncentration for pooled normal pig plasma was2 15.0 ± 13.8 mg/dL, and intraassaya nd interassayC Vw ere 6.4% and 11.4%, respectively. Thrombin-antithrombinIII complex (TAT )concentrations were quantitatedusing the Enzygnost TATmicro enzymeimmunoassay( Dade Behring,M arburg, Germany), whichh as previously beendemonstrated to cross-react with porcine TAT (15) . IntraassayCVwas 5.6% and interassay CV was10.3% for apig plasma poolcontaining 38.4 ±1.6 ng/ml TAT.
Species-specific PT Preparation of pig thromboplastin (p-ThP)
Brains were collected froms laughterhousep igs and storeda t 4°C in 0.9% saline until washing with 0.9% saline and removal of largeblood vessels. Each brainwas homogenized in 500 ml of phosphate-buffered saline (PBS) forfiveminutesatfull speedin aW aring (Torrington, CT) commercial blender and the homogenate placed into 50 ml conical vials and centrifugedf or 15 minutes at 2100 xg.The resulting supernatants were retained as p-ThP,pooled,and frozenat-20°C in 1mlaliquots.
Modified PT assay p-ThP wast haweda nd centrifugeda t2 100 xgf or 5m inutes. Supernatant wascollectedand diluted 1:20 with HEPES buffer (Sigma,St. Louis, MO)containing 100 μ M25% phosphatidylcholine: 75% phosphatidylserine (PCPS) lipidvesicles(HaematologicT echnologies, Essex Junction, VT), and equilibrated for 10 minutes at 39°C.A ssays were performed at 39°C using a Beckman-Coulter( Fullerton, CA) DU640 spectrophotometer equippedwith atemperature-controlledcuvette holder.T operformthe procedure, 200 μ lofpig plasma and 400 μ lofdiluted p-ThP were added to each prewarmed cuvette and allowedt o equilibratefor twominutes. Thereaction wasinitiatedbythe addition of 200 μ lofCaCl 2 .Absorbance measurements were made at 880nmevery 0.4 seconds for atotal of 120 seconds. Meanclot formation time for pooled normal pigplasma was35.2 ± 0.7 seconds. Intra-assaya nd inter-assayc oefficientso fv ariation were 5.1% and 6.5%, respectively. Thromboelastography TEG monitors changes in the viscoelastic properties of aforming clot. Blood is delivered into asamplecup and clotting initiatedspontaneouslyorusing variousagonists. Apin is suspended in the blood by atorsion wire and monitoredfor motion as the pin is repeatedlyrotated through the blood in a10-second cycle. Increased blood viscosity increases resistancetopin rotation and deflects the pin. Thed eflection is translatedi nto output measuredinmmofamplitude, whichincreases as blood viscosity increases. Va riousstandard parameters are calculated, including reaction time (R), coagulation time (K), α -angle,maximum amplitude (MA), and time to reach MA (tMA). Rr eflectst he period of latencyfrom the start time to initialclot formation. K reflectsthe timefrom Runtil astandardized levelofclot firmness is reached (amplitude =20mm).The α -angle is ameasure of the kinetics of clot development. MA is the maximum amplitude attainedand reflects the maximum firmness of the clot. For furtherdescription seeChandler (16) .
Twoadditional TEG parametersw ere calculated,maximum velocity (MaxVe l),and timetoMaxVel (tMaxVel). Calculations were made usingavariation of the methodsreported by Sorensen et al. (17) . Amplitude data were recorded at 5secondintervals. Ve locity of clot formation wasc alculated everyf ives econds based on the change in amplitude within a3 0s econdw indow spanning 15 seconds on eitherside of each time point. Thehighest velocity within agiven TEGrun wastermedMaxVel and expressed in mm/min. The timeatthe occurrence of MaxVel was designated tMaxVel and expressed in minutes.
TEG wasperformed at each blood sampling time, except immediately followingthe 90 and 360 μ g/kg doses. The assaywas performed at 39ºC using the model5 000 TEG (Haemoscope, Skokie,IL). Fiftyμlofp-ThPdiluted1:250 with 0.9%saline or 100 μg/ml equine tendoncollagen (COLL; Helena Laboratories, Beaumont, TX) were preloaded into each reaction cup.The final dilution of p-ThP in the reaction mixture was1:1750. Thefinal collagenc oncentration in the reaction mixture was1 4μ g/ml. TEG wasperformed using 50 μl of saline as acontrol to allow confirmation thatt he clotting observedi nr esponset ot he two agonists waspredominantlydue to agonist activity,asopposed to contact with the cup wall. Unaltered whole blood (300 μ l) was delivered to each cup within one minute of collection to initiate clotting. Theprocedure wasterminatedshortlyafter MA wasattained.
TEGw as performed in triplicate. Thesingle value for each calculatedTEG parameter wasderivedbyaveraging,with elimination of as ingle value when the CV exceeded 10%. Using p-ThPa sa gonist,t he meanC Vw ithin replicates (intra-assay) were 4.9%, 5.5%, 5.2%, 4.4%, 1.9%, 3.1%, and 5.7% for MaxVe l, tMaxVel,R,K, α -angle,MA, and tMA, respectively.Mean CV were similarfor COLL.
The dilution of p-ThP used wasselected to be dilute enough to optimizes ensitivity to rFVIIa activity (17), while ensuring thatthe tissue factor pathway would be dominant over reactions initiatedb ycontactwith the cup wall (intrinsic pathway). Atitration wasperformed to characterize the response to aseries of p-ThPdilutions. Blood wascollectedvia catheter fromfour additional anesthetizedswine. Wholeblood wasdelivered to TEG cupsc ontaining diluted p-ThP to yield final dilutions of 1:7, 1:175, 1:350, 1:700, 1:1750, and 1:3500. The dose-response relationship between p-ThPdilutionsand clot formation velocity profileswas similar to thatreported fortissue factor dilutionsin human blood (17) .The dilution used in the present study gave satisfactorysensitivity to rFVIIa.
Platelet aggregometry(PA )
PA wasperformed in triplicateusing aP ACKS-4 optical platelet aggregometer (Helena Laboratories, Beaumont, TX). Standard adenosine diphosphate (ADP;Helena Laboratories, Beaumont, TX)and COLL reagent solutions containing 50 mM CaCl 2 were used. Stock preparations of these agonists were used undiluted and diluted1:5, 1:10,and 1:20 with PBS. This yielded concentrations of 20, 4, 2, and 1μMfor ADP and 10, 2, 1, and 0.5 μg/ml for COLL, respectively,inthe final plateletrichplasma reaction mixture. Citrated blood wascentrifuged at 200xgtoyield plateletrichplasma and at 1000 xgtoproduce platelet poor plasma. Allreactions were performed at 39°C using prewarmed reagents. Platelet poor plasma wasusedtorepresent 100% aggregation for each sample. To initiate aggregation, 50 μl agonist solution was added to 450 μl stirring platelet rich plasma.
Pathology
Samplesf rom kidney,l ung, mesentery, heart,a nd skeletal muscle were collected within 10 minutes post-mortem and fixed in formalin. All samplesw ere embedded in paraffin, sectioned, and stainedusing hematoxylin and eosin, Masson's Trichrome, and phosphotungstenacidhematoxylin. Tissueswere examined under light microscopyb yab oard-certified veterinaryp athologist whowas blindedtotreatment group.
Statisticalanalysis
Continuous data were analyzed by analysis of variance using the General Linear Models( GLM) procedure of SAS ( 18) . Where parametersw ere monitored over time,s uch as MAP,T AT,a nd others, effects of rFVIIaand injuryw ere examinedaccounting for the repeated nature of the measurements. When examining within group changes over time,anew variable wasgenerated by subtracting the time 0value fromeach subsequent value within each animal. Thesevariableswere used in statistical analysis but not listed in results. All appropriate data areexpressed as mean ± SEM. Discrete data, such as survival, were analyzed by Fisher's ExactTestusing the FREQ procedure of SAS.
Results
MAP wasn ot affectedb yt reatment during the dosee scalation phase (Fig. 1) .Ear capillary BT wasnot affectedbytreatment at anydose and averaged 139 ± 6seconds across times and treatment groups. Ap rogressive increase in FVIIa ctivity waso bservedw ith each increasing dose of rFVIIa, followedbyadecline at 30 minutesp ost-injury( p<.01; Fig. 2 ). There wasn oe ffect of either rFVIIa or injuryonHct,PLT or fibrinogen concentration. Overallmean Hct,fibrinogen, and PLTwere 25.6 ± 0.9%, 172 ± 2mg/ dL, and 384 ± 11 x1 0 3 /μl, respectively.The coagulation times obtained from both the standard and pig-specific PT assays decreased significantly in the rFVIIa group beginning at the 90 μg/kg dose and remained shorter at each timep oint thereafter (p<.01), with no additionalc hange associated with the injury phase (Fig. 3) . Throughout the study period,aPTTwas lowerin the rFVIIa thaninthe saline group, with baseline means of 12.2 ± 0.2 and 14.6 ± 0.3 seconds, respectively (p<.01), and no subsequentchangesinthese baseline valuesineithergroupthroughout the study.Therewere no differences in TATconcentration betweengroups at anytime studied (Fig. 4) . Whenexamined on the basis of within group change from baseline, TATwas increased by both rFVIIaadministration and by injury (Fig. 4) .
TEG resultsfor p-ThP and COLL aredepicted in tables 1and 2, respectively.Initial clot formation time(R) wasconsistently shortened by rFVIIa, regardless of agonist.W hen p-ThP was used,c lot development progressed morer apidlya fter rFVIIa treatment, as reflected by increased MaxVe la nd α -angle and shortened tMaxVel and tMA (Table 1) .Using COLL,tMaxVel wasd ecreased and both α -angle and MA were increased by rFVIIa treatment (Table 2) .At30minutespost-injury, MaxVel increased (p<.05)inthe rFVIIagroupwhen COLL wasthe agonist.U sing p-ThP,M axVel forb oth groups decreasedf ollowing injury, sucht hat the rFVIIagroupm ean wasn ol onger greater thanbaseline and the saline group meandeclinedbelow its respective withing roupb aseline (p<.05). Also followingi njury, tMaxVel and Rw ere increased (p<.01)c ompared to baseline within the saline group. In the rFVIIagroup, tMaxVel remained statistically shorter thanbaseline,while Rincreased such that it wasnolonger statisticallyshorter than baseline (Table 1) .
There wasn oe ffect of rFVIIa or injuryo np lateleta ggregation in response to anyconcentration of agonist. Percent plateleta ggregation decreased with each decreasing agonist concentration. Acrosstreatmentsand times, aggregation in response to ADPwas 43 ± 2, 19 ± 2, 9 ± 2, and 4 ± 1% for concentrations of 20, 4, 2, and 1μMADP,respectively. Aggregation was77 ± 1, 54 ± 2, 20 ± 2and 9 ± 3% in response to 10, 2, 1and 0.5 μg/ml COLL. ACTremained stable in the saline group butdeclinedsignificantly in the rFVIIa group (Table 3) .
During the injuryp hase,b lood loss wass imilarb etween groups, with meanblood lossesof812 ± 71 ml and 893 ± 71 ml for the rFVIIaa nd saline groups, respectively.A t3 0m inutes post-injury, MAP declinedfrom 64 ± 2mmHgto39 ± 3mmHg in the surviving rFVIIa animals and from68 ± 2mmHgto21 ± 3mmHginthe surviving saline animals, and washigher(p<.05) in the rFVIIagroup (Fig. 1) . Post-injurysurvivaltime wassimilarfor the twogroups;animals in the rFVIIaand saline groups survived33.5 ± 8.8 and 28.5 ± 8.8 minutes after injury. Survival to 30 minuteswas 50%ineach group; by 60 minutes post-injury, 33% of animals survivedinthe rFVIIagroup, compared with 0% in the saline group. No evidenceofintravascularcoagulation was noted during histopathologicalexamination of collected tissues.
Discussion
FVII activity wase levatedi nad ose-dependent manneri nt he treateda nimals, consistent with previous reports in humans (19) (20) (21) and swine (5, 8) . Thedecline in concentration after the final dose wasapproximatelytwice that expected basedonthe half-life of rFVIIainhumans (147 min; 13). This mayreflect a difference in rFVIIametabolism between humans and swine,or mayberelated to the period of haemorrhagic shock thatfollowed the final rFVIIadose. Administration of rFVIIaconsistentlyshortens PT in normal (21),coagulopathic (2, 19, 22, 23) , and anticoagulated (21) humans, as well as in normal(6-8) and coagulopathic pigs (4, 5) . The standard reagent used to initiate coagulation in the PT is rabbit brain thromboplastin (24) .Aconfounding factor in animalresearch with rFVIIa is thatt he tissue factor-FVII interaction is species-specific ( 11, 12) . Because rabbit thromboplastin efficiently induces coagulation in humanplasma (11), species-spe- cificity is not an issue in humanc linical practicea nd research withrFVIIa. In studieswith swine,however,species-specificity must be considered. Bothrabbit and humanthromboplastins induce coagulation more efficiently in humanplasma thaninporcine plasma.Additionally, porcine thromboplastin inducesc oagulation more efficiently in porcine plasma thaninhuman plasma (11, 12) . WhenrFVIIa is administered to swine,amixtureof native porcine FVIIa and human rFVIIae xists; both of these must reactwith pig tissue factor in vivo.Incontrast, both FVIIa's must interact with rabbit tissue factor in astandard PT in vitro .It is therefore conceivablethat adose of rFVIIathat is not active in the pig in vivo could yield a"false positive" in vitro when using astandard PT withrabbit-derivedreagents. To minimizethis potential problem, we used amodified PT that incorporated p-ThP.
Beginningwith the 90 μg/kgdose, rFVIIamaximallyshortened pig-specific PT,suggesting that rFVIIaat90μg/kg in pigs maximallyenhances the tissue factor pathway to the extent detectable in aPT. In humans, 5μg/kg rFVIIasubmaximallyshortenedPT while a10μg/kg dose maximallyshortenedPT (20) . The dose requiredtosubmaximallyshorten species-specific PT in swine cannot be determinedfrom the present databut that dose appears to be less than90μg/kg. In both the aPTT and ACT, clotting is initiatedbyanegatively charged reagent throught he intrinsic( factor XII) pathway. Shortened aPTT after administration of rFVIIa has been reported in humans (2, 19, 23) butnot swine (4) . Although aPTT wasnot altered by rFVIIa administration in this study, ACTwas shortened after rFVIIa treatment, with the effect first observed withthe 90 μg/kg dose. This effect mayhavebeen duetodirect activation of factor XbyrFVIIa (25)but this is not probablesince aPTT wasnot altered. Alternatively,ACT mayhavebeen shortened by an effect of rFVIIa on platelets (9) . Tissue factor-independentbindingofrFVIIa is believedtoenhancethe capacity of platelets to generate thrombin, leading to enhancedplateletrecruitment and clot formation. We therefore examinedthe platelet aggregation response to maximaland submaximal doses of ADP and COLL, hypothesizing that rFVIIamay enhance platelet aggregation in response to submaximalagonist doses. We observed no effect of rFVIIaonplateletaggregation, however, suggesting eithert hat plateletf unction wasn ot enhancedo rt hat the methods used were notabletodetect alterationsinfunction.
In standard TEG, the clotting reaction is initiated via the intrinsic system (16) .Inrecent years,however,ithas become apparent thatthe tissue factor pathway (extrinsic system) plays the major roleinhaemostasis (24) . Thus,weusedthe physiological agonists p-ThP and COLL to initiate clotting throughthe swine tissue factor pathway and throughacellularmechanism, respectively. Clear effectsofrFVIIa were observedwith TEG. In blood from rFVIIa-treatedpigs, initialclot formation washastened, regardless of agonist.I na ddition, clot development proceeded morerapidlyinclots initiatedbyp-ThPand maximum clot firmness wasincreased in clots initiated by COLL.Inpatients undergoing livert ransplantation,r FVIIa shortenedRa nd K, and increased α -angle,indicating more rapid clot initiation and development (23) . In apreviousstudy in swine,TEG parameters were notaffected by rFVIIa (4) . In thatstudy,however,animals were haemodiluteda nd hypothermic, whichm ay have influenced TEGresults. Thepresentdataconfirminswinethe findings of Sorensenetal. (17) that identified MaxVel and tMaxVel as sensitivep arameters ford etecting rFVIIa-induced changes in humanblood.Results also indicatethat sensitivity of MaxVel to rFVIIamay differwith different agonists.
Despite evidencefrom laboratorytests suggesting enhancement of the coagulation system, rFVIIa didnot alter BT.BTis commonlyu sedt om onitor changes in haemostasis associated with plateletdisorders (26) . Thereason forthe lackofeffect of rFVIIa on BT mayhavebeen thatrFVIIa didnot affect platelet adhesion under the noncoagulopathicc onditions of the pig model used. This possibilityi ss upported by the absence of an observable effect of rFVIIa on platelet aggregation.
In twos tudiesu sing swine with induced coagulopathies, treatment with rFVIIa reduced blood loss when used as an adjuncttopacking after severe liverinjury (4, 5) . In normal swine, rFVIIa didnot reduce blood loss after severe liverinjuryintwo studies (7, 8) , butdid reduce blood loss in another (6) . In astudy involving aortic injury, rFVIIa didnot reduce blood loss butincreased rebleeding pressureafter resuscitation (27) . In the present study,b lood loss wasnot reduced. Differing resultsamong studiesmay be explained by the differingusesofrFVIIa (adjunct to packing versusalone), to different typesofhaemorrhage (arterial versusvenous), or to differences in coagulation status. In twoo ft he threes tudiesi nw hich blood loss wasr educed by rFVIIa, the pigs were coagulopathic (4, 5) . In studiesinw hich blood loss wasunchanged,coagulation status wasnormal (7, 8, 27 ). Reports of clinicalefficacyofrFVIIa in patients with normalc oagulation arer are (21),w hile reports of efficacyi np atients with abnormalcoagulation have beennumerous (1) .Itis possible that the potential for haemostatic improvement with rFVIIa is greater in the presence of acoagulopathy.
MAP wasnot affectedbyrFVIIa prior to the injuryphase of the experiment. At 30 minutes post-injury, however, MAP in the surviving animals in the rFVIIa group wasnearlydouble that of the saline group. Similar findings have beenreported by some (7)but not others (8) . It is possible that this increased ability to maintain MAP following rFVIIareflectsanincreased ability of formed clots to maintain in the face of increasing blood pressure following auto-or fluid resuscitation, as recentlyreported in an aortic injurymodel (27) .Inspite of the apparentlybeneficialeffect on MAP, survivalwas notaffected by rFVIIa in the present study.
The primarysafetyconcern pertaining to the use of rFVIIais the possibility for intravascular coagulation. Althoughthis drug has beensafe to date,itremains important to specifically considerthis question as the potential uses for the drug expand (2) . In the present study,T AT,a ni ndicator of thrombin generation, waselevatedafter rFVIIa treatment in the rFVIIa group and was elevatedinboth treatment groups after 30 minutes of hypotension following severe hepaticinjury. Schreiber et al.(8) also reported elevatedT AT after rFVIIa administration in swine but concluded thati ntravascularc oagulation wasn ot present because PLTand fibrinogen concentrations were stable and there wasnoevidenceof premortem thrombus formation. In the present study,n eitherP LT nor fibrinogen concentration were affected either by rFVIIa or liverinjury. TEG results were equivocal. Followinghaemorrhage, MaxVel in response to p-ThPdeclinedi nb oth groups butr emained numericallyh igheri nt he rFVIIa group. BothRand tMaxVel were prolonged in the saline group butnot the rFVIIagroup. These changes mayreflect the earlys tageso fapotentiallyc oagulopathic state resulting from haemorrhage. The p-ThP TEG data suggest that rFVIIadid not exacerbatethe situation and mayhavebeen somewhat protective in this regard. Histologic examination revealed no evidenceo f intravascular coagulation in eithergroup. Takentogether,these data indicate that rFVIIatreatment wasassociatedwith aslight systemic activation of thrombin.Systemic activation occurred to agreater degree in both groups as aresultofsevere haemorrhage and shockbut wasstill without apparentconsumption of fibrinogen and platelets in either treatment group.
We have demonstrated that in vivo administration of as little as 90 μg/kg rFVIIa in swine results in changes in coagulation that are detectable in vitro, using physiologically relevant agonists in av arietyofassays. Morerapidclot formation after rFVIIa administration wasdetected in both whole blood and plasma. Despite clear evidenceofrFVIIa activity in the porcine system, in vivo haemostasis wasn ot measurablya ltered by rFVIIa. These results suggest thatr FVIIa mayn ot improve upon the normal haemostatic mechanism to producem ore rapid haemostasis in the absence of coagulopathy. Although there wasamild systemic activation of thrombin,therewas no evidenceofsystemic intravascular coagulation associated with rFVIIa. Human rFVIIapossessessufficient activity in the porcine systemtoallowmeaningful interpretation of results. Theuse of species-specific in vitro assays to monitor rFVIIa therapy addstothat interpretation.
